Chemokine receptors as therapeutic targets: Why aren't there more drugs?

European Journal of Pharmacology

Volumn 746, Issue , 2015, Pages 363-367

  Solari, Roberto ^c   Pease, James E ^b   Begg, Malcolm ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Chemokine; Chemokine receptor; Drug discovery; Inflammation

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; GLYCOSAMINOGLYCAN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; IMMUNOLOGIC FACTOR; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; DRUG EFFICACY; DRUG TARGETING; HUMAN; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG DEVELOPMENT; EARLY TERMINATION OF CLINICAL TRIAL; METABOLISM; MOLECULARLY TARGETED THERAPY; TRENDS;

ANIMALS; ANTI-HIV AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; EARLY TERMINATION OF CLINICAL TRIALS; HUMANS; IMMUNOLOGIC FACTORS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; RECEPTORS, CHEMOKINE;

EID: 84920171419     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.06.060     Document Type: Article

References (49)

1. K. Asagoe, K. Yamamoto, A. Takahashi, K. Suzuki, A. Maeda, M. Nohgawa, N. Harakawa, K. Takano, N. Mukaida, K. Matsushima, M. Okuma, and M. Sasada Down-regulation of CXCR2 expression on human polymorphonuclear leukocytes by TNF-alpha J. Immunol. 160 1998 4518 4525
2. L. Ajram, M. Begg, R. Slack, J. Cryan, D. Hall, S. Hodgson, A. Ford, A. Barnes, D. Swieboda, A. Mousnier, and R. Solari Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists Eur. J. Pharmacol. 729 2014 75 85
3. M. Brave, A. Farrell, S. Ching Lin, T. Ocheltree, S. Pope Miksinski, S.L. Lee, H. Saber, J. Fourie, C. Tornoe, B. Booth, W. Yuan, K. He, R. Justice, and R. Pazdur FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation Oncology 78 2010 282 288
4. R. Bonecchi, N. Polentarutti, W. Luini, A. Borsatti, S. Bernasconi, M. Locati, C. Power, A. Proudfoot, T.N. Wells, C. Mackay, A. Mantovani, and S. Sozzani Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-gamma in human neutrophils J. Immunol. 162 1999 474 479
5. A. Cahn, S. Hodgson, R. Wilson, J. Robertson, J. Watson, M. Beerahee, S.C. Hughes, G. Young, R. Graves, D. Hall, S. van Marle, and R. Solari Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study BMC Pharmacol. Toxicol. 14 2013 14
6. L.M. Campbell, P.J. Maxwell, and D.J. Waugh Rationale and means to target pro-inflammatory interleukin-8 (CXCL8) signaling in cancer Pharmaceuticals 6 2013 929 959
7. P.H. Carter Chemokine receptor antagonism as an approach to anti-inflammatory therapy: 'just right' or plain wrong? Curr. Opin. Chem. Biol. 6 2002 510 525
8. M. Congreve, C.J. Langmead, J.S. Mason, and F.H. Marshall Progress in structure based drug design for G protein-coupled receptors J. Med. Chem. 54 2011 4283 4311
9. D.J. Dairaghi, P. Zhang, Y. Wang, L.C. Seitz, D.A. Johnson, S. Miao, L.S. Ertl, Y. Zeng, J.P. Powers, A.M. Pennell, P. Bekker, T.J. Schall, and J.C. Jaen Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose Clin. Pharmacol. Ther. 89 2011 726 734
10. Y. Feng, T.J. Mitchison, A. Bender, D.W. Young, and J.A. Tallarico Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds Nat. Rev. Drug Discov. 8 2009 567 578
11. D.J. Fox, J. Reckless, H. Lingard, S. Warren, and D.J. Grainger Highly potent, orally available anti-inflammatory broad-spectrum chemokine inhibitors J. Med. Chem. 52 2009 3591 3595
12. M. Hanefeld, E. Schell, I. Gouni-Berthold, M. Melichar, I. Vesela, D. Johnson, S. Miao, T.J. Sullivan, J.C. Jaen, T.J. Schall, and P. Bekker The CCX140-B Diabetes Study Group. Orally-administered chemokine receptor CCR2 antagonist CCX140-B in type 2 diabetes: a pilot double-blind, randomized clinical trial J. Diabetes Metab. 3 2012 1 8
13. D. Hartl, S. Krauss-Etschmann, B. Koller, P.L. Hordijk, T.W. Kuijpers, F. Hoffmann, A. Hector, E. Eber, V. Marcos, I. Bittmann, O. Eickelberg, M. Griese, and D. Roos Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases J. Immunol. 181 2008 8053 8067
14. A.M. Holmes, R. Solari, and S.T. Holgate Animal models of asthma: value, limitations and opportunities for alternative approaches Drug Discov. Today 16 2011 659 670
15. R. Horuk Chemokine receptor antagonists: overcoming developmental hurdles Nat. Rev. Drug Discov. 8 2009 23 33
16. H. Imaoka, H. Campbell, I. Babirad, R.M. Watson, M. Mistry, R. Sehmi, and G.M. Gauvreau TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge Clin. Exp. Allergy 12 2011 1740 1746
17. E. Jacoby, R. Bouhelal, M. Gerspacher, and K. Seuwen The 7 TM G-protein-coupled receptor target family ChemMedChem 1 2006 761 782
18. I. Kalatskaya, Y.A. Berchiche, S. Gravel, B.J. Limberg, J.S. Rosenbaum, and N. Heveker AMD3100 is a CXCR7 ligand with allosteric agonist properties Mol. Pharmacol. 75 2009 1240 1247
19. D. Karpova, K. Spohn, D. Chudziak, E. Wiercinska, M. Schulz, A.R. Pettit, J.P. Levesque, B. Romagnoli, K. Patel, E. Chevalier, K. Dembowsky, and H. Bonig The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor Leukemia 27 2013 2322 2331
20. T. Kenakin, and A. Christopoulos Signalling bias in new drug discovery: detection, quantification and therapeutic impact Nat. Rev. Drug Discov. 12 2013 205 216
21. S. Keshav, T. Vaňásek, Y. Niv, R. Petryka, S. Howaldt, M. Bafutto, I. Rácz, D. Hetzel, O.H. Nielsen, S. Vermeire, W. Reinisch, P. Karlén, S. Schreiber, T.J. Schall, P. Bekker Prospective Randomized Oral-Therapy Evaluation in Crohn's Disease Trial-1 PROTECT-1 Study Group A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease PLoS One 8 3 2013 e60094
22. M.H. Khandaker, G. Mitchell, L. Xu, J.D. Andrews, R. Singh, H. Leung, J. Madrenas, S.S. Ferguson, R.D. Feldman, and D.J. Kelvin Metalloproteinases are involved in lipopolysaccharide- and tumor necrosis factor-alpha-mediated regulation of CXCR1 and CXCR2 chemokine receptor expression Blood 93 1999 2173 2185
23. A.L. Lazaar, L.E. Sweeney, A.J. MacDonald, N.E. Alexis, C. Chen, and R. Tal-Singer SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans Br. J. Clin. Pharmacol. 72 2011 282 293
24. D. Maussang, A. Mujic-Delic, F.J. Descamps, C. Stortelers, P. Vanlandschoot, M. Stigter-van Walsum, H.F. Vischer, M. van Roy, M. Vosjan, M. Gonzalez-Pajuelo, G.A. van Dongen, P. Merchiers, P. van Rompaey, and M.J. Smit Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo J. Biol. Chem. 288 2013 29562 29572
25. B.E. Miller, K. Smart, S. Mistry, C.L. Ambery, J.C. Bloomer, P. Connolly, D. Sanderson, T. Shreeves, R. Smith, and A.L. Lazaar The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers Eur. J. Drug Metab. Pharmacokinet. 2014 (PMID:24504700) (epub ahead of print)
26. D.H. McDermott, Q. Liu, J. Ulrick, N. Kwatemaa, S. Anaya-O'Brien, S.R. Penzak, J.O. Filho, D.A. Priel, C. Kelly, M. Garofalo, P. Little, M.M. Marquesen, D. Hilligoss, R. Decastro, T.A. Fleisher, D.B. Kuhns, H.L. Malech, and P.M. Murphy The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome Blood 118 2011 4957 4962
27. W.G. Nichols, H.M. Steel, T. Bonny, K. Adkison, L. Curtis, J. Millard, K. Kabeya, and N. Clumeck Hepatotoxicity observed in clinical trials of aplaviroc (GW873140) Antimicrob. Agents Chemother. 52 2008 858 865
28. A. Palani, and J.R. Tagat Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists J. Med. Chem. 49 2006 2851 2857
29. J. Pease, and R. Horuk Chemokine receptor antagonists J. Med. Chem. 55 2012 9363 9392
30. J.E. Pease, and R. Horuk Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4 Expert Opin. Drug Discov. 9 2014 467 483
31. A.E.I. Proudfoot, C.A. Power, and M.K. Schwarz Anti-chemokine small molecule drugs: a promising future? Expert Opin. Investig. Drugs 19 2010 345 355
32. C.A. Power Knock out models to dissect chemokine receptor function in vivo J. Immunol. Methods 273 2003 73 82
33. S.R. Pulley CCR5 antagonists: from discovery to clinical efficacy Kuldeep Neote, Gordon L. Letts, Bernhard Moser, Chemokine Biology - Basic Research and Clinical Application 2 2007 Birkhauser Basel 145 163
34. M.P. Rettig, G. Ansstas, and J.F. DiPersio Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4 Leukemia 26 2012 34 53
35. A.L. Robertson, G.R. Holmes, A.N. Bojarczuk, J. Burgon, C.A. Loynes, M. Chimen, A.K. Sawtell, B. Hamza, J. Willson, S.R. Walmsley, S.R. Anderson, M.C. Coles, S.N. Farrow, R. Solari, S. Jones, L.R. Prince, D. Irimia, G.E. Rainger, V. Kadirkamanathan, M.K. Whyte, and S.A. Renshaw A zebrafish compound screen reveals modulation of neutrophil reverse migration as an anti-inflammatory mechanism Sci. Transl. Med. 6 2014 225ra29
36. M.M. Rosenkilde, T. Benned-Jensen, T.M. Frimurer, and T.W. Schwartz The minor binding pocket: a major player in 7TM receptor activation Trends Pharmacol. Sci. 31 2010 567 574
37. T.J. Schall, and A.E.I. Proudfoot Overcoming hurdles in developing successful drugs targeting chemokine receptors Nat. Rev. Immunol. 11 2011 355 363
38. J.K. Singh, B.M. Simões, R.B. Clarke, and N.J. Bundred Targeting IL-8 signalling to inhibit breast cancer stem cell activity Expert Opin. Ther. Targets 17 2013 1235 1241
39. J.M. Subramaniam, G. Whiteside, K. McKeage, and J.C. Croxtall Drugs 72 2012 1293 1298
40. T. Sullivan, Z. Miao, D.J. Dairaghi, A. Krasinski, Y. Wang, B.N. Zhao, T. Baumgart, L.S. Ertl, A. Pennell, L. Seitz, J. Powers, R. Zhao, S. Ungashe, Z. Wei, L. Boring, C.L. Tsou, I. Charo, R.D. Berahovich, T.J. Schall, and J.C. Jaen CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice Am. J. Physiol. Renal Physiol. 305 2013 F1288 F1297
41. P.P. Tak, A. Balanescu, V. Tseluyko, S. Bojin, E. Drescher, D. Dairaghi, S. Miao, V. Marchesin, J. Jaen, T.J. Schall, and P. Bekker Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial Ann. Rheum. Dis. 72 2013 337 344
42. A. Takeda, J.Z. Baffi, M.E. Kleinman, W.G. Cho, M. Nozaki, K. Yamada, H. Kaneko, R.J. Albuquerque, S. Dridi, K. Saito, B.J. Raisler, S.J. Budd, P. Geisen, A. Munitz, B.K. Ambati, M.G. Green, T. Ishibashi, J.D. Wright, A.A. Humbles, C.J. Gerard, Y. Ogura, Y. Pan, J.R. Smith, S. Grisanti, M.E. Hartnett, M.E. Rothenberg, and J. Ambati CCR3 is a target for age-related macular degeneration diagnosis and therapy Nature 460 2009 225 230
43. A.J. Venkatakrishnan, X. Deupi, G. Lebon, C.G. Tate, G.F. Schertler, and M.M. Babu Molecular signatures of G-protein-coupled receptors Nature 494 2013 185 194
44. S.A. Villeda, J. Luo, K.I. Mosher, B. Zou, M. Britschgi, G. Bieri, T.M. Stan, N. Fainberg, Z. Ding, A. Eggel, K.M. Lucin, E. Czirr, J.S. Park, S. Couillard-Després, L. Aigner, G. Li, E.R. Peskind, J.A. Kaye, J.F. Quinn, D.R. Galasko, X.S. Xie, T.A. Rando, and T. Wyss-Coray The ageing systemic milieu negatively regulates neurogenesis and cognitive function Nature 477 2011 90 94
45. A. Viola, and A.D. Luster Chemokines and their receptors: drug targets in immunity and inflammation Annu. Rev. Pharmacol. Toxicol. 48 2008 171 197
46. J.D. Violin, D.G. Soergel, and M.W. Lark Beta-arrestin-biased ligands at the AT1R: a novel approach to the treatment of acute heart failure Drug Discov. Today: Ther. Strateg. 9 2012 e149 e154
47. J.D. Violin, D.G. Soergel, G. Boerrigter, J.C. Burnett Jr.; and M.W. Lark GPCR biased ligands as novel heart failure therapeutics Trends Cardiovasc. Med. 23 2013 242 249
48. H. Watz, A. Kirsten, F. Pedersen, C. Trusley, F. Xuan, X. Ma, J. Zhao, H. Magnussen, and S. Khalilieh The effects of The CXCR2 antagonist Sch 527123 on neutrophilic airway inflammation following ozone challenge in healthy subjects - a dose response study Am. J. Respir. Crit. Care Med. 185 2012 A2733
49. A.J. Zweemer, J. Toraskar, L.H. Heitman, and A.P. Ijzerman Bias in chemokine receptor signalling Trends Immunol. 35 2014 243 252